Consolidated Portfolio Review Corp’s Procter & Gamble PG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-28,175
Closed -$4.33M 291
2025
Q3
$4.33M Sell
28,175
-735
-3% -$115K 0.54% 46
2025
Q2
$4.61M Buy
28,910
+181
+0.6% +$29.5K 0.64% 32
2025
Q1
$4.9M Buy
28,729
+247
+0.9% +$41.4K 0.78% 26
2024
Q4
$4.77M Buy
28,482
+16,671
+141% +$2.84M 0.76% 25
2024
Q3
$2.05M Sell
11,811
-606
-5% -$103K 0.46% 55
2024
Q2
$2.05M Buy
12,417
+7,321
+144% +$1.2M 0.48% 56
2024
Q1
$827K Sell
5,096
-8,889
-64% -$1.39M 0.22% 116
2023
Q4
$2.05M Sell
13,985
-1,202
-8% -$178K 0.47% 61
2023
Q3
$2.22M Buy
15,187
+585
+4% +$89.4K 0.54% 47
2023
Q2
$2.22M Buy
14,602
+398
+3% +$60K 0.53% 52
2023
Q1
$2.11M Buy
+14,204
New +$2.03M 0.57% 47

Other funds holding PG

Consolidated Portfolio Review Corp's PG Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Procter & Gamble (PG) in Q4 2025, closing a stake of 28,175 shares — an estimated $4.33M sold.

Consolidated Portfolio Review Corp first reported a position in PG in Q1 2023 and held it in 11 quarters. The position peaked at $4.9M in Q1 2025. 4,023 funds tracked by Wall St. Rank hold PG as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Procter & Gamble position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 28,175 Procter & Gamble shares in Q4 2025, an estimated $4.33M.
  • Consolidated Portfolio Review Corp first reported a position in Procter & Gamble in Q1 2023 and held it in 11 quarters.
  • Consolidated Portfolio Review Corp's Procter & Gamble position peaked at $4.9M in Q1 2025.
  • 4,023 funds tracked by Wall St. Rank held Procter & Gamble as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.